TIAA CREF Investment Management LLC increased its position in Seres Therapeutics, Inc. (NASDAQ:MCRB) by 14.4% during the first quarter, Holdings Channel reports. The fund owned 110,076 shares of the biotechnology company’s stock after buying an additional 13,825 shares during the period. TIAA CREF Investment Management LLC’s holdings in Seres Therapeutics were worth $1,241,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the company. American International Group Inc. boosted its position in shares of Seres Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 10,977 shares of the biotechnology company’s stock worth $124,000 after buying an additional 727 shares during the last quarter. Fox Run Management L.L.C. bought a new position in shares of Seres Therapeutics during the first quarter worth approximately $136,000. Bank of Montreal Can boosted its position in shares of Seres Therapeutics by 33.7% in the first quarter. Bank of Montreal Can now owns 19,144 shares of the biotechnology company’s stock worth $216,000 after buying an additional 4,829 shares during the last quarter. Parametric Portfolio Associates LLC boosted its position in shares of Seres Therapeutics by 1.3% in the first quarter. Parametric Portfolio Associates LLC now owns 21,335 shares of the biotechnology company’s stock worth $240,000 after buying an additional 279 shares during the last quarter. Finally, Teachers Advisors LLC boosted its position in shares of Seres Therapeutics by 43.5% in the fourth quarter. Teachers Advisors LLC now owns 41,101 shares of the biotechnology company’s stock worth $407,000 after buying an additional 12,462 shares during the last quarter. Institutional investors own 75.28% of the company’s stock.

Shares of Seres Therapeutics, Inc. (NASDAQ MCRB) traded up 0.36% on Tuesday, hitting $13.75. The company had a trading volume of 4,084 shares. The company has a 50 day moving average price of $12.61 and a 200 day moving average price of $10.72. Seres Therapeutics, Inc. has a 1-year low of $8.85 and a 1-year high of $15.09. The firm’s market capitalization is $557.04 million.

Seres Therapeutics (NASDAQ:MCRB) last issued its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by $0.10. The company had revenue of $3 million for the quarter, compared to analysts’ expectations of $3 million. Seres Therapeutics had a negative return on equity of 80.21% and a negative net margin of 441.38%. The business’s revenue for the quarter was up .0% on a year-over-year basis. During the same period last year, the company posted ($0.70) EPS. On average, equities analysts forecast that Seres Therapeutics, Inc. will post ($2.48) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Seres Therapeutics, Inc. (MCRB) Stake Boosted by TIAA CREF Investment Management LLC” was first published by Daily Political and is owned by of Daily Political. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://www.dailypolitical.com/2017/08/15/seres-therapeutics-inc-mcrb-stake-boosted-by-tiaa-cref-investment-management-llc.html.

MCRB has been the topic of a number of recent analyst reports. Zacks Investment Research upgraded Seres Therapeutics from a “hold” rating to a “buy” rating and set a $13.00 price target on the stock in a research report on Wednesday, July 5th. Canaccord Genuity set a $20.00 price target on Seres Therapeutics and gave the stock a “buy” rating in a research report on Monday, June 12th. Cowen and Company restated a “buy” rating on shares of Seres Therapeutics in a research report on Friday, May 19th. Cantor Fitzgerald set a $16.00 price target on Seres Therapeutics and gave the stock a “buy” rating in a research report on Thursday, May 4th. Finally, BidaskClub upgraded Seres Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, July 25th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $17.00.

About Seres Therapeutics

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Want to see what other hedge funds are holding MCRB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Seres Therapeutics, Inc. (NASDAQ:MCRB).

Institutional Ownership by Quarter for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.